NCT06868381
A Trial of Baricitinib in Patients With Cardiac Sarcoidosis
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 6 versions: 6 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Recruitment opened
- Eligibility criteria expanded, about 9 words
- Secondary endpoints: details revised at 4 of 17 entries
- Site details revised
- Notable Primary completion date: Jan 1, 2028 to Jul 1, 2028
- Start date: Jul 1, 2025 to Apr 1, 2026
- Study completion date: Apr 1, 2028 to Dec 1, 2028
- Notable Start date: May 12, 2025 to Jul 1, 2025v4
- Notable Start date: Apr 1, 2025 to May 12, 2025
- Site contact updated
- Minor Secondary endpoints revised (17)v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Proportion of patients with resolution of cardiac FDG uptake on PET-CT
Timeframe: From baseline to end of treatment at 16 weeks
Secondary (17)
Percent change in FDG avidity (SUVmax) in the cardiac lesion with greatest FDG avidity on PET-CT
Percent change in total cardiac metabolic activity on FDG PET-CT
Proportion of patients with resolution of extracardiac FDG uptake on PET-CT
Percent change in FDG avidity (SUVmax) in up to six extracardiac lesions on PET-CT
Percent change in total extracardiac metabolic activity on FDG PET-CT
Show 12 moreShow less
Proportion of patients with resolution of cardiac FDG uptake on PET-CT
Change in sarcoidosis disease activity assessment
Change in fatigue assessment
Change from Baseline in Physician Disease Activity Visual Analogue Scale (VAS)
Change from Baseline in Patient Disease Activity Visual Analogue Scale (VAS)
Changes in ACE laboratory assessment
Changes in high-sensitivity troponin I laboratory assessment
Changes in NT-proBNP laboratory assessment
Changes in total IgG laboratory assessment
Changes in ESR laboratory assessment
Changes in CRP laboratory assessment
Number of participants with safety endpoints of interest
Arms and interventions
baricitinib + steroid-sparing drug +/- glucocorticoid taperExperimental
* Participants will be treated with baricitinib 4 mg daily for up to 16 weeks in combination with a background steroid sparing medication * Participants who are on steroids at the time of enrollment will continue the steroid at a dose of prednisone (or equivalent) ≤ 20mg PO daily at Baseline and complete an 8 week taper of their steroid medication per a standardized protocol
Drugs: Baricitinib (LY3009104) 4 mg
Sites
1 site in 1 country
- Stanford UniversityPalo Alto, California, United States